CN106319069B - 一种精确测定病源细胞的试剂盒及其应用 - Google Patents
一种精确测定病源细胞的试剂盒及其应用 Download PDFInfo
- Publication number
- CN106319069B CN106319069B CN201610861587.4A CN201610861587A CN106319069B CN 106319069 B CN106319069 B CN 106319069B CN 201610861587 A CN201610861587 A CN 201610861587A CN 106319069 B CN106319069 B CN 106319069B
- Authority
- CN
- China
- Prior art keywords
- sequence
- kit
- cells
- pathogenic
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 57
- 239000002751 oligonucleotide probe Substances 0.000 claims abstract description 68
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims abstract description 66
- 230000008685 targeting Effects 0.000 claims abstract description 62
- 238000012544 monitoring process Methods 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000027455 binding Effects 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 110
- 239000000523 sample Substances 0.000 claims description 56
- 238000001514 detection method Methods 0.000 claims description 45
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical group C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 35
- 235000019152 folic acid Nutrition 0.000 claims description 22
- 239000011724 folic acid Substances 0.000 claims description 22
- 238000004445 quantitative analysis Methods 0.000 claims description 21
- 238000003753 real-time PCR Methods 0.000 claims description 17
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 239000007850 fluorescent dye Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 229940014144 folate Drugs 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 39
- 230000009871 nonspecific binding Effects 0.000 abstract description 14
- 230000003321 amplification Effects 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 14
- 229960000304 folic acid Drugs 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 12
- 238000012986 modification Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 108020005243 folate receptor Proteins 0.000 description 7
- 102000006815 folate receptor Human genes 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 125000004149 thio group Chemical group *S* 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000006166 lysate Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 101150029707 ERBB2 gene Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010069941 DNA receptor Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000008238 LHRH Receptors Human genes 0.000 description 3
- 108010021290 LHRH Receptors Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- JOAQINSXLLMRCV-UHFFFAOYSA-N 4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}benzoic acid Chemical compound C1=NC2=NC(N)=NC(O)=C2N=C1CNC1=CC=C(C(O)=O)C=C1 JOAQINSXLLMRCV-UHFFFAOYSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000009129 Ear Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035610 Pleural Neoplasms Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- -1 antibody Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000018280 neoplasm of mediastinum Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 208000014680 small intestine neoplasm Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
组份 | 用量 |
Realtime PCR Master Mix | 12.5μL |
扩增引物 | 300nM |
探针 | 100nM |
扩增模板 | 2.5μL |
ddH<sub>2</sub>O | 补至25μL |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610861587.4A CN106319069B (zh) | 2016-09-28 | 2016-09-28 | 一种精确测定病源细胞的试剂盒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610861587.4A CN106319069B (zh) | 2016-09-28 | 2016-09-28 | 一种精确测定病源细胞的试剂盒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106319069A CN106319069A (zh) | 2017-01-11 |
CN106319069B true CN106319069B (zh) | 2020-02-14 |
Family
ID=57820888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610861587.4A Active CN106319069B (zh) | 2016-09-28 | 2016-09-28 | 一种精确测定病源细胞的试剂盒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106319069B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109781975B (zh) * | 2017-11-14 | 2022-05-06 | 河南乾坤科技有限公司 | 富集循环稀有细胞的试剂及方法 |
CN111676271B (zh) * | 2020-05-28 | 2023-10-24 | 广州烨善生物科技有限公司 | 一种原位杂交探针 |
CN114964996A (zh) * | 2022-06-10 | 2022-08-30 | 江苏格诺生物科技有限公司 | 一种免疫磁珠负向富集循环肿瘤细胞的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE497165T1 (de) * | 2004-10-06 | 2011-02-15 | Wellstat Biologics Corp | Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung |
CN102830228B (zh) * | 2011-06-15 | 2015-01-21 | 格诺思博生物科技(上海)有限公司 | 定量分析循环肿瘤细胞的试剂及试剂盒 |
CN103045720B (zh) * | 2011-10-17 | 2014-08-20 | 格诺思博生物科技(上海)有限公司 | 检测病源细胞的靶向性分子及其应用 |
CN103320502B (zh) * | 2012-03-21 | 2016-12-14 | 格诺思博生物科技(上海)有限公司 | 微寡聚核苷酸pcr检测的方法、组成和应用 |
CN105675870B (zh) * | 2016-04-05 | 2017-08-04 | 上海美吉生物医药科技有限公司 | 一种用于检测循环肿瘤细胞侵袭力的试剂盒 |
-
2016
- 2016-09-28 CN CN201610861587.4A patent/CN106319069B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN106319069A (zh) | 2017-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7858325B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
CN109825586B (zh) | 用于肺癌检测的DNA甲基化qPCR试剂盒及使用方法 | |
CN109097477B (zh) | 一种用于乳腺癌诊断的circRNA标志物及其应用 | |
CN110607270B (zh) | 一种基于核酸适体免疫pcr共同表征外泌体膜标志物和rna的方法 | |
CN106319069B (zh) | 一种精确测定病源细胞的试剂盒及其应用 | |
AU2018364987A1 (en) | Non-coding RNA for detection of cancer | |
CN108660215B (zh) | 检测circMAN1A2和circRNF13试剂的应用及试剂盒 | |
CN108796075B (zh) | 检测circRNF13和LOC284454试剂的应用及试剂盒 | |
CN110229899B (zh) | 用于结直肠癌早期诊断或预后预测的血浆标记物组合 | |
AU2007211251A1 (en) | Method to detect breast cancer cells | |
CN114717305A (zh) | Nr1d1、junb、rorc作为药物性-急性肾损伤的诊断标记应用 | |
CN105624166B (zh) | 一种检测人膀胱移行细胞癌细胞的核酸适配体及其在制备检测制剂中的应用 | |
CN109971832A (zh) | 一种检测基因突变的试剂盒、方法及其用途 | |
CN111944821B (zh) | 一种结肠癌核酸适体的组织样本快速筛选及其在检测制剂中的应用 | |
CN108660213B (zh) | 检测三种非编码rna试剂的应用及试剂盒 | |
KR20090053222A (ko) | 체액 내 대장암 마커로서의 cxcl-16유전자 및 이를이용한 대장암의 진단 및 치료에의 용도 | |
CA2328377A1 (en) | A novel method of diagnosing, monitoring, and staging prostate cancer | |
CN112322743A (zh) | 检测人sept9基因甲基化的试剂盒及其使用方法、应用 | |
JP2002527757A (ja) | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 | |
CN103320502B (zh) | 微寡聚核苷酸pcr检测的方法、组成和应用 | |
JP2002526760A (ja) | 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法 | |
CN113005199B (zh) | 用于微卫星不稳定性检测的引物组合物、试剂盒及应用 | |
CN113957149B (zh) | 一种检测甲胎蛋白基因和pgr13基因表达量的试剂盒及其应用 | |
KR102461422B1 (ko) | 양성 종양 또는 결절로부터 암을 구분하기 위한 바이오마커 | |
CN111004843B (zh) | 基于单链dna肽连接酶的jak1基因特定突变检测试剂盒及方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171024 Address after: 450044 Henan province Zhengzhou city Xu Zhuang Road Newton international B No. 97 building 6 floor Applicant after: HENAN QIANKUN TECHNOLOGY CO.,LTD. Address before: 226010 Nantong Province Economic and Technological Development Zone, new East Road, No. 9, No. Applicant before: GENOSABER BIOTECHNOLOGY NANTONG Co.,Ltd. Applicant before: GENOSABER BIOTECH (SHANGHAI) Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230509 Address after: Building 26, Lane 908, Ziping Road, Zhoupu Town, Pudong New Area, Shanghai, 201318 Patentee after: Jiangsu Genuo Biotechnology Co.,Ltd. Address before: 450044 6 / F, building B, Newton international, No. 97, Xuzhuang Road, Jinshui District, Zhengzhou City, Henan Province Patentee before: HENAN QIANKUN TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: No. 9 Xindong Road, Development Zone, Nantong City, Jiangsu Province, 226010 Patentee after: Jiangsu Geno Biotechnology Group Co.,Ltd. Country or region after: China Address before: Building 26, Lane 908, Ziping Road, Zhoupu Town, Pudong New Area, Shanghai, 201318 Patentee before: Jiangsu Genuo Biotechnology Co.,Ltd. Country or region before: China |